Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats

Alcohol

Volumn 43, Issue 8, 2009, Pages 581-592

  Bell, Richard L ^a,b   Eiler II, Bill J A ^a,b   Cook, Jason B ^a   Rahman, Shafiqur ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Alcohol consumption; Cytisine; Drug addiction; Lobeline; Nicotinic receptor; Selectively bred rats

Indexed keywords

ALCOHOL; CYTISINE; LOBELINE; NICOTINIC RECEPTOR; SODIUM CHLORIDE;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRINKING BEHAVIOR; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FLUID INTAKE; MALE; NONHUMAN; RAT; REACTION TIME; TARGET ORGAN; TREATMENT DURATION;

ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; CYSTINE; DOPAMINE; DRINKING; LIGANDS; LOBELINE; MALE; RATS; RECEPTORS, NICOTINIC;

RATTUS;

EID: 71149108953     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.alcohol.2009.09.027     Document Type: Article

References (82)

1. Aistrup G.L., Marszalec W., and Narahashi T. Ethanol modulation of nicotinic acetylcholine receptor currents in cultured cortical neurons. Mol. Pharmacol. 55 (1999) 39-49
2. Bell R.L., Rodd Z.A., Hsu C.C., Lumeng L., Li T.-K., Murphy J.M., et al. Effects of concurrent access to a single or multiple concentrations of ethanol on ethanol intake by periadolescent high-alcohol-drinking rats. Alcohol 33 (2004) 107-115
3. Bell R.L., Rodd Z.A., Murphy J.M., and McBride W.J. Use of selectively bred alcohol-preferring rats to study alcohol abuse, relapse and craving. In: Preedy V.R., and Watson R.R. (Eds). Comprehensive Handbook of Alcohol Related Pathology Vol. 3 (2005), Academic Press, New York, NY 151-1533
4. Bell R.L., Rodd Z.A., Schultz J.A., Peper C.L., Lumeng L., Murphy J.M., and McBride W.J. Effects of short deprivation and re-exposure intervals on the ethanol drinking behavior of selectively bred high alcohol-consuming rats. Alcohol 42 (2008) 407-416
5. Benwell M.E., and Balfour D.J. The influence of lobeline on nucleus accumbens dopamine and locomotor responses to nicotine in nicotine-pretreated rats. Br. J. Pharmacol. 125 (1998) 1115-1119
6. Blomqvist O., Ericson M., Engel J.A., and Soderpalm B. Accumbal dopamine overflow after ethanol: localization of the antagonizing effect of mecamylamine. Eur. J. Pharmacol. 334 (1997) 149-156
7. Blumenthal S.J. Women's mental health: The new national focus. Ann. N.Y. Acad. Sci. 789 (1996) 1-16
8. Blumenthal, S. J. (1997). Women and substance abuse: a new national focus. National Institute on Drug Abuse Conference on Substance Abuse in Women, 1997. Available at http://www.nida.nih.gov.
9. Brienza R.S., and Stein M.D. Alcohol use disorders in primary care: do gender-specific differences exist. J. Gen. Intern. Med. 17 (2002) 387-397
10. Butt C.M., King N.M., Stitzel J.A., and Collins A.C. Interaction of the nicotinic cholinergic system with ethanol withdrawal. J. Pharmacol. Exp. Ther. 308 (2004) 591-599
11. Carbonnelle E., Sparatore F., Canu-Boido C., Salvagno C., Baldani-Guerra B., Terstappen G., et al. Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes. Eur. J. Pharmacol. 471 (2003) 85-96
12. Cardoso R.A., Brozowski S.J., Chavez-Noriega L.E., Harpold M., Valenzuela C.F., and Harris R.A. Effects of ethanol on recombinant human neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 289 (1999) 774-780
13. Chavez-Noriega L.E., Gillespie A., Stauderman K.A., Crona J.H., Claeps B.O., Elliott K.J., et al. Characterization of the recombinant human neuronal nicotinic acetylcholine receptors alpha3beta2 and alpha4beta2 stably expressed in HEK293 cells. Neuropharmacology 39 (2000) 2543-2560
14. Cicero T.J. A critique of animal analogues of alcoholism. In: Majchrowicz E., and Noble E.P. (Eds). Biochemistry and Pharmacology of Ethanol Vol. 2 (1979), Plenum Press, New York, NY 533-560
15. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48 (2005) 3474-3477
16. Covernton P.J., and Connolly J.G. Differential modulation of rat neuronal nicotinic receptor subtypes by acute application of ethanol. Br. J. Pharmacol. 122 (1997) 1661-1668
17. Dwoskin L.P., and Crooks P.A. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 63 (2002) 89-98
18. Ericson M., Lof E., Stomberg R., Chau P., and Soderpalm B. Nicotinic acetylcholine receptors in the anterior, but not posterior, ventral tegmental area mediate ethanol-induced elevation of accumbal dopamine levels. J. Pharmacol. Exp. Ther. 326 (2008) 76-82
19. Ericson M., Lof E., Stomberg R., Chau P., and Soderpalm B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J. Pharmacol. Exp. Ther. 329 (2009) 225-230
20. Farook J.M., Lewis B., Gaddis J.G., Littleton J.M., and Barron S. Lobeline, a nicotinic partial agonist attenuates alcohol consumption and preference in male C57BL/6J mice. Physiol. Behav. 97 (2009) 503-506
21. Files F.J., Samson H.H., Denning C.E., and Marvin S. Comparison of alcohol-preferring and nonpreferring selectively bred rat lines. II. Operant self-administration in a continuous-access situation. Alcohol. Clin. Exp. Res. 22 (1998) 2147-2158
22. Greenbaum L., Kanyas K., Karni O., Merbl Y., Olender T., Horowitz A., et al. Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotine cholinergic receptor genes. Mol. Psychiatry 11 (2006) 312-322
23. Griffin J.F. A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery. Adv. Drug Deliv. Rev. 54 (2002) 851-861
24. Harrod S.B., Dwoskin L.P., Crooks P.A., Klebaur J.E., and Bardo M.T. Lobeline attenuates d-methamphetamine self administration in rats. J. Pharmacol. Exp. Ther. 298 (2001) 172-179
25. Hendrickson L.M., Zhao-Shea R., and Tapper A.R. Modulation of ethanol drinking-in-the dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. Psychopharmacology (Berl.) 204 (2009) 563-572
26. Hogg R.C., and Bertrand D. Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. Biochem. Pharmacol. 73 (2007) 459-468
27. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals (1996), National Academy Press, Washington, DC
28. Kamens H.M., McKinnon C.S., Li N., Helms M.L., Belknap J.K., and Phillips T.J. The alpha3 subunit of the nicotine acetylcholine receptor is a candidate gene for ethanol stimulation. Genes Brain Behav (2008) [Epub ahead of print], October 21, 2009.
29. Kamens H.M., and Phillips T.J. A role for neuronal nicotinic acetylcholine receptors in ethanol-induced stimulation, but not cocaine- or methamphetamine-induced stimulation. Psychopharmacology (Berl.) 196 (2008) 377-387
30. Kuzmin A., Jerlhag E., Liljequist S., and Engel J. Effects of subunit selective nAch receptors on operant ethanol self-administration and relapse-like ethanol-drinking behavior. Psychopharmacology (Berl.) 293 (2008) 99-108
31. Larsson A., and Engel J.A. Neurochemical and behavioral studies on ethanol and nicotine interactions. Neurosci. Biobehav. Rev. 27 (2004) 713-720
32. Larsson A., Jerlhag E., Svensson L., Soderpalm B., and Engel J.A. Is an alpha-conotoxin MII-sensitive mechanism involved in the neurochemical, stimulatory, and rewarding effects of ethanol?. Alcohol 34 (2004) 239-250
33. Lester D., and Freed E.X. Criteria for an animal model of alcoholism. Pharmacol. Biochem. Behav. 1 (1973) 103-107
34. Lof E., Olausson P., deBejczy A., Stomberg R., McIntosh J.M., Taylor J.R., et al. Nicotine acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues. Psychopharmacology (Berl.) 195 (2007) 333-343
35. Lopez-Moreno J.A., Scherma M., Rodriguez de Fonseca F., Gonzalez-Cuevas G., Fratta W., and Navarro M. Changed accumbal responsiveness to alcohol in rats pretreated with nicotine or the cannabinoid receptor agonist WIN 55,212-2. Neurosci. Lett. 433 (2008) 1-5
36. McBride W.J., and Li T.-K. Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents. Crit. Rev. Neurobiol. 12 (1998) 339-369
37. McKinney W.T. Overview of the past contributions of animal models and their changing place in psychiatry. Semin. Clin. Neuropsychiatry 6 (2001) 68-78
38. Mihalak K.B., Carroll F.I., and Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 70 (2006) 801-805
39. Miller D.K., Crooks P.A., and Dwoskin L.P. Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology 39 (2000) 2654-2662
40. Miller D.K., Crooks P.A., Teng L., Witkin J.M., Munzar P., Goldberg S.R., et al. Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J. Pharmacol. Exp. Ther. 296 (2001) 1023-1034
41. Miller D.K., Crooks P.A., Zheng G., Grinevich V.P., Norrholm S.D., and Dwoskin L.P. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters and diminished affinity at alpha4beta2* and alpha7* nAChRs. J. Pharmacol. Exp. Ther. 310 (2004) 1035-1045
42. Miller D.K., Harrod S.B., Green T.A., Wong M.Y., Bardo M.T., and Dwoskin L.P. Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats. Pharmacol. Biochem. Behav. 74 (2003) 279-286
43. Miller D.K., Lever J.R., Rodvelt K.R., Baskett J.A., Will M.J., and Kracke G.R. Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend. 89 (2007) 282-291
44. Mineur Y.S., Eibl C., Young G., Kochevar C., Papke R.L., Gündisch D., et al. Cytisine-based nicotinic partial agonists as novel antidepressant compounds. J. Pharmacol. Exp. Ther. 329 (2009) 377-386
45. Mineur Y.S., Somenzi O., and Picciotto M.R. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology 52 (2007) 1256-1262
46. Murphy J.M., Stewart R.B., Bell R.L., Badia-Elder N.E., Carr L.G., McBride W.J., et al. Phenotypic and genotypic characterization of the Indiana University rat lines selectively bred for high and low alcohol preference. Behav. Genet. 32 (2002) 363-388
47. Narahashi T., Soderpalm B., Ericson M., Olausson P., Engel J.A., Zhang X., et al. Mechanisms of alcohol-nicotine interactions: alcoholics versus smokers. Alcohol. Clin. Exp. Res. 25 (2001) 152S-156S
48. National Institute on Alcohol Abuse and Alcoholism. Five Year Strategic Plan FY07-11: Alcohol Across the Lifespan (2007), Department of Health and Human Services, Washington, DC
49. Nelson C.B., Heath A.C., and Kessler R.C. Temporal progression of alcohol dependence symptoms in the U.S. household population: results from the National Comorbidity Survey. J. Consult. Clin. Psychol. 66 (1998) 474-483
50. Neugebauer N.M., Harrod S.B., Stairs D.J., Crooks P.A., Dwoskin L.P., and Bardo M.T. Lobelane decreases methamphetamine self-administration in rats. Eur. J. Pharmacol. 571 (2007) 33-38
51. Nunn-Thompson C.L., and Simon P.A. Pharmacotherapy for smoking cessation. Clin. Pharm. 8 (1989) 710-720
52. Olausson P., Jentsch J.D., Krueger D.D., Tronson N.C., Nairn A.C., and Taylor J.R. Orbitofrontal cortex and cognitive-motivational impairments in psychostimulant addiction. Ann. N.Y. Acad. Sci. 1121 (2007) 610-638
53. Oster S.M., Toalston J.E., Kuc K.A., Pommer T.J., Murphy J.M., Lumeng L., et al. Effects of multiple alcohol deprivations on operant ethanol self-administration by high-alcohol-drinking replicate rat lines. Alcohol 38 (2006) 155-164
54. Owens J.C., Balogh S.A., McClure-Begley T.D., Butt C.M., Labarca C., Lester H.A., et al. Alpha 4 beta 2* nicotinic acetylcholine receptors modulate the effects of ethanol and nicotine on the acoustic startle response. Alcohol. Clin. Exp. Res. 27 (2003) 1867-1875
55. Papke R.L., and Heinemann S.F. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta2 subunit. Mol. Pharmacol. 45 (1994) 142-149
56. Papke R.L., and Porter-Papke J.K. Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis. Br. J. Pharmacol. 137 (2002) 49-61
57. Parker M.J., Beck A., and Luetje C.W. Neuronal nicotinic receptor β2 and β4 subunits confer large differences in agonist binding affinity. Mol. Pharmacol. 54 (1998) 1132-1139
58. Picciotto M.R., Addy N.A., Mineur Y.S., and Brunzell D.H. It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog. Neurobiol. 84 (2008) 329-342
59. Rahman S., Lopez-Hernandez G., Corrigall W.A., and Papke R.L. Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction. CNS Neurol. Disord. Drug Targets 7 (2008) 422-441
60. Reavill C., Walther B., Stolerman I.P., and Testa B. Behavioral and pharmacokinetic studies on nicotine, cytisine, lobeline. Neuropharmacology 29 (1990) 619-624
61. Rehm J., Room R., Graham K., Monteiro M., Gmel G., and Sempos C.T. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease-an overview. Addiction 98 (2003) 1209-1228
62. Ribeiro-Carvalho A., Lima C.S., Filgueiras C.C., Manhaes A.C., and Abreu-Villaca Y. Nicotine and ethanol interact during adolescence: effects on the central cholinergic systems. Brain Res. 1232 (2008) 48-60
63. Rigbi A., Kanyas K., Yakir A., Greenbaum L., Pollak Y., Ben-Asher E., et al. Why do young women smoke? V. Role of direct and interactive effects of nicotinic cholinergic receptor gene variation on neurocognitive function. Genes Brain Behav. 7 (2008) 164-172
64. Rodd Z.A., Bell R.L., Kuc K.A., Murphy J.M., Lumeng L., and McBride W.J. Effects of concurrent access to multiple ethanol concentrations and repeated deprivations on alcohol intake of high alcohol-drinking (HAD) rats. Addict. Biol. 14 (2009) 152-164
65. Rodd Z.A., Bell R.L., Sable H.J.K., Murphy J.M., and McBride W.J. Recent advances in animal models of alcohol craving and relapse. Pharmacol. Biochem. Behav. 79 (2004) 439-450
66. Rodd-Henricks Z.A., McKinzie D.L., Murphy J.M., McBride W.J., Lumeng L., and Li T.-K. The expression of an alcohol deprivation effect in the high-alcohol-drinking replicate rat lines is dependent on repeated deprivations. Alcohol. Clin. Exp. Res. 24 (2000) 747-753
67. Room R., Babor T., and Rehm J. Alcohol and public health. Lancet 365 (2005) 519-530
68. Samson H.H., Files F.J., Denning C., and Marvin S. Comparison of alcohol-preferring and nonpreferring selectively bred rat lines. I. Ethanol initiation and limited access operant self-administration. Alcohol. Clin. Exp. Res. 22 (1998) 2133-2146
69. Schlaepfer I.R., Hoft N.R., Collins A.C., Corley R.P., Hewitt J.K., Hopfer C.J., et al. The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol. Psychiatry 63 (2008) 1039-1046
70. Sinclair J.D., and Senter R.J. Increased preference for ethanol in rats following deprivation. Psychon. Sci. 8 (1967) 11-12
71. Sinclair J.D., Walker S., and Jordan W. Behavioral and physiological changes associated with various durations of alcohol deprivation in rats. Q. J. Stud. Alcohol 34 (1973) 744-757
72. Slater Y.E., Houlihan L.M., Maskell P.D., Exley R., Bermudez I., Lukas R.J., et al. Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology 44 (2003) 503-515
73. Soderpalm B., Ericson M., Olausson P., Blomqvist O., and Engel J.A. Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav. Brain Res. 113 (2000) 85-96
74. Stauderman K.A., Mahaffym L.S., Akong M., Velicelebi G., Chavez-Noriega L.E., Crona J.H., et al. Characterization of human recombinant neuronal nicotinic acetlycholine receptor subunit combinations α2β4, α3β4 and α4β4 stably expressed in HEK293 cells. J. Pharmacol. Exp. Ther. 284 (1998) 777-789
75. Steensland P., Simms J.A., Holgate J., Richards J.K., and Bartlett S.E. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 12518-12523
76. Teng L., Crooks P.A., Sonsalla P.K., and Dwoskin L.P. Lobeline and nicotine evoke [3H] overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. J. Pharmacol. Exp. Ther. 280 (1997) 1432-1444
77. Tizabi Y., Bai L., Copeland Jr. R.L., and Taylor R.E. Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol. 42 (2007) 413-416
78. Tutka P., and Zatonski W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol. Rep. 58 (2006) 777-798
79. Tzankova V., and Danchev N. Cytisine-from ethnomedical use to the development as a natural alternative for smoking cessation. Biotechnol. Biotechnol. Equip. 21 (2007) 151-160
80. Wilhelm C.J., Johnson R.A., Lysko P.G., Eshleman A.J., and Janowsky A. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system. J. Pharmacol. Exp. Ther. 310 (2004) 1142-1151
81. Wilsnack S.C., Klassen A.D., Schur B.E., and Wilsnack R.W. Predicting onset and chronicity of women's problem drinking: a five-year longitudinal analysis. Am. J. Public Health 81 (1991) 305-318
82. Xiao Y., Baydyuk M., Wang H.P., Davis H.E., and Kellar K.J. Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells. Bioorg. Med. Chem. Lett. 14 (2004) 1845-1848